

Alzheimer's disease and cytokine IL-10 gene polymorphisms: is there an association?

A doença de Alzheimer e os polimorfismos no gene da citocina IL-10: há alguma associação?

Carolina Antunes Magalhães¹, Maria das Graças Carvalho¹, Lirlândia Pires de Sousa¹, Paulo Caramelli², Karina Braga Gomes¹

ABSTRACT

Alzheimer's disease (AD) is the most common form of dementia. In the last 15 years, a new theory has proposed the autoimmune mechanism as a trigger for AD. Studies on the association between AD and inflammatory biomarkers have yielded controversial results. Interleukin-10 (IL-10), an anti-inflammatory mediator, has been pointed out as one of the main cytokines associated with the occurrence of AD. Moreover, treatment that increases IL-10 levels could be a potential therapy for AD, since this cytokine acts on amyloid and pro-inflammatory molecule reduction. Based on the current literature, this study reviews evidence regarding the role of *IL-10* polymorphisms in the context of AD, which has been shown to be of paramount importance for attenuating neuroinflammation, cognitive dysfunction and neurodegeneration.

Keywords: Alzheimer's disease; inflammation; Interleukin-10.

RESUMO

A doença de Alzheimer (DA) é a forma mais comum de demência. Nos últimos 15 anos, uma nova teoria propõe um mecanismo autoimune como o gatilho para a DA. Associações entre DA e biomarcadores inflamatórios têm sido registradas, contudo com resultados controversos. A interleucina-10 (IL-10), um mediador anti-inflamatório, tem sido apontada como uma das principais citocinas associadas com a ocorrência de DA. Além disso, os tratamentos que aumentam os níveis de IL-10 podem ser uma terapia potencial para DA, uma vez que esta citocina atua sobre a redução de substância amiloide e de moléculas pró-inflamatórias. Baseando-se em literaturas atuais, este estudo revisa evidências relacionadas com o papel da IL-10 e seus polimorfismos no contexto da DA, o qual se mostrou ser de fundamental importância para atenuar a neuroinflamação, a disfunção cognitiva e a neurodegeneração.

Palavras-chave: doença de Alzheimer; inflamação; interleucina-10.

Alzheimer's disease (AD), the most common form of dementia, is a global public health problem challenging the older generation¹. Alzheimer's disease is a neurodegenerative disorder characterized by injury to brain regions responsible for controlling memory and other cognitive functions. In this way, this disease compromises the ability to learn, reason, communicate, and carry out daily activities, and is accompanied by personality and behavioral changes².

According to the Alzheimer's Association, in the United States, one person develops AD every 67 seconds. By 2050, one case every 33 seconds is predicted, resulting in one million new cases per year¹. Nitrini *et al.* found a prevalence for dementia in seven percent of the elderly, aged 65 or older, in Latin America³.

Neuropathology in AD is characterized by altered formation of amyloid- β (A β) plaques and hyperphosphorylation

of the tau protein associated with neurofibrillary tangles^{4,5}. According to Rosenberg *et al.*⁶, genotype-phenotype correlations of AD provide a comprehensive appreciation of the spectrum of disease causation. The inflammatory process is another main pathophysiological factor associated with AD^{7,8}.

In the last 15 years, a new theory has proposed the autoimmune mechanism as a trigger for AD. This theory involves a dysregulation of the blood-brain barrier, neurons, microglia, astrocytes and multiple cytokines^{9,10,11}. As reviewed by Naert and Rivest, activated microglia and astrocytes secrete inflammatory cytokines and chemokines, while age-related inflammation and chronic infection with herpes viruses might contribute to the systemic inflammation¹².

Microglia activation is supposed initially to be a result of tissue injury and amyloid plaque deposition due to a cytotoxic

¹ Universidade Federal de Minas Gerais, Faculdade de Farmácia, Departamento de Análises Clínicas e Toxicológicas, Belo Horizonte MG, Brasil;

² Universidade Federal de Minas Gerais, Faculdade de Medicina, Departamento de Clínica Médica, Belo Horizonte MG, Brasil.

Correspondence: Karina Braga Gomes; Faculdade de Farmácia da UFMG; Avenida Antônio Carlos, 6627; 31270-901 Belo Horizonte MG, Brasil; E-mail: karinabgb@gmail.com

Support: Fundação de Amparo à Pesquisa de Minas Gerais (FAPEMIG), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES). LPS, MGC, PC and KBG are grateful to CNPq Research Fellowship (PQ).

Conflict of interest: There is no conflict of interest to declare.

Received 09 February 2017; Received in final form 04 June 2017; Accepted 13 June 2017.

response in the brain^{13,14}. Activated microglia and astrocyte clusters at sites of neuritic plaques release a variety of inflammatory mediators¹⁵, including pro- and anti-inflammatory cytokines that play critical roles in the development and progression of AD^{16,17,18,19}.

The associations between AD and inflammatory biomarkers, including the interleukins IL-1 β , IL-2, IL-4, IL-6, IL-8, IL-12, IL-18, interferon (IFN)- γ , tumor necrosis factor (TNF)- α , transforming growth factor (TGF)- β , and the C-reactive protein have been registered with controversial results²⁰. However, interleukin-10 (IL-10), an anti-inflammatory mediator, has been pointed out as one of the main cytokines associated with the occurrence of AD^{5,9,10}. Therefore, this study reviewed evidence of the role of IL-10 and its genetic polymorphisms in the context of AD. Our hypothesis is that decreased levels of IL-10, an anti-inflammatory cytokine, and its polymorphisms contribute to an increase in the inflammatory process, which should favour the development of AD, reinforcing the link between inflammation and cognitive decline in elderly people.

METHODS

Our search was conducted in Pubmed, the Cochrane Library, Science Direct, Scopus and Web of Science databases with the terms “Alzheimer’s disease”, “inflammation”, “interleukin-10”, and studies reporting on “associations between Alzheimer’s disease and interleukin-10”, with no date restrictions. In this search, 60 works published between 1989 and 2016, in the English language, were identified and included in the present review.

IL-10 and immunomodulation

Cytokines are small proteins secreted by activated cells. They can affect other target cells or even the same cell that secreted these cytokines. Cytokines are responsible for the communication between cells and play an important role in the physiological and pathological inflammation processes²¹. Interleukins, one of the main types of cytokines, are small glycoproteins, secreted by activated leukocytes. Interleukins are involved in macrophages and T lymphocyte activation, proliferation and toxicity. Defects of interleukin production may be associated with several disorders. There are more than 36 types of interleukins chronologically numbered in the order of their discovery, one of them being IL-10²².

Interleukin-10 is a 36-KDa homodimeric cytokine described by Fiorentino *et al.* as a “cytokine synthesis inhibitory factor”, because of its ability to suppress cytokine production from all T cell types²³. The main IL-10 sources *in vivo* are monocytes, macrophages, dendritic, B, NK and mast cells, T-cells, as well as neutrophils and eosinophils.

In monocytic cells, IL-10 influences antigen presentation, release of immune mediators and phagocytosis²¹.

Interleukin-10 opposes the actions of the pro-inflammatory cytokines and appears to be a suppressor of both immunoproliferative and inflammatory responses in the brain, reducing synthesis of pro-inflammatory cytokines, suppressing cytokine receptor expression, and inhibiting receptor activation^{21,24}. Expression of the pro-inflammatory cytokines with a central role in inflammation and cell death, such as IL-1, IL-2, IL-6, IL-8, IL-12, TNF- α , and IFN- γ , are negatively controlled by the immunomodulatory action of IL-10²³.

Alzheimer’s disease and IL-10 effects

It is known that a chronic inflammatory process accompanies AD. However, it remains unclear whether inflammation is a reaction to the pathology of AD or a contribution to the onset, or progression, of the disease²⁵. The observation of the reactive astrocytes and activated microglia cells, associated with senile plaques in AD, reinforces the inflammatory mechanisms in the pathogenesis of this disease. This mechanism is also supported by the observation of a decreased incidence of AD in patients who receive long-term nonsteroidal anti-inflammatory drugs²⁶.

According to Combarros *et al.*²⁵, certain combinations of genetic variants in the regulatory regions of the two genes, i.e. *IL-6-174G/C* (rs1800795) and *IL-10-1082A/G* (rs1800896) contribute to chronic inflammation in elderly people, increasing the risk of AD. An imbalance between pro-inflammatory and anti-inflammatory cytokines may, therefore, be an important phenomenon in AD. This hypothesis is supported by studies, which described an increase of seven- to ten-fold in the production of IL-1 β over IL-10 levels in AD patients when compared with control subjects²⁶. Indeed, Rota *et al.* did not detect abnormal levels of IL-10 in either cerebrospinal fluid or serum of AD patients²⁷.

Richwine *et al.* observed that a peripheral injection with lipopolysaccharide, in IL-10-deficient mice, causes a prominent cognitive deficit when compared with wild-type mice²⁸. Kiyota *et al.*¹⁰ demonstrated that IL-10 significantly reduced neuroinflammation, enhanced neurogenesis and improved spatial cognitive dysfunction in transgenic AD mouse models. They showed that treatment with IL-10-adenovirus of double-transgenic mice expressing familial AD mutants of amyloid precursor protein+presenilin-1 (APP+PS1 Tg), could suppress astro/microgliosis. According to the authors, these findings support the concept that IL-10 may ameliorate neuroinflammation, cognitive dysfunction and neurodegeneration.

Corroborating these findings, Henderson²⁹ suggested that post-menopausal administration of estrogens may delay the onset, or contribute to the prevention of AD²⁹ by increasing the secretion of IL-10 from microglial cells^{30,31}. Moreover, resveratrol, a natural polyphenol reported to have anti-inflammatory

effects, is able to up-regulate both *IL-10* gene expression and *IL-10* levels, which could explain its neuroprotective properties³². Bagyinszky et al.²² disclosed that *IL-10* treatment could be a potential therapy for AD since this cytokine could act on amyloid reduction by inducing the production of anti-inflammatory molecules, and inhibition of pro-inflammatory cytokines, probably by down-regulating their expression.

However, Guillot-Sestier et al.³³ found that crossing the (APP+PS1 Tg) mouse model of cerebral amyloidosis with animals deficient in *IL-10* demonstrated that genetic blockade of *IL-10* mitigates cerebral amyloidosis in APP/PS1 mice. In line with these results, Chakrabarty *et al.* reported that enhanced *IL-10* expression in brains of APP transgenic mice leads to increased A β accumulation and worsening of behavioral deficits³⁴. These results suggest that rebalancing cerebral innate immunity and promoting beneficial neuroinflammation may be more efficacious than generalized anti-inflammatory therapy for AD. Indeed, according to Bryson and Lynch³⁵, anti-inflammatory therapy has not been proven to be of value in the treatment of AD and inflammatory changes, once a certain stage of inflammation is reached.

Zheng et al.³⁶ reviewed studies in order to understand the importance of the role of cytokines or neuroinflammation in AD etiology and pathogenesis, suggesting the imbalance of pro- and anti-inflammatory activity in AD. According to them, inconsistent outcomes involve *IL-10*: this cytokine drives macrophage polarization – M1 to M2, which is associated with deactivation of microglia; overexpressing tau increases secretion of *IL-10* in rat microglia, which show greater phagocytosis of microspheres; knock-out mice show the benefit of *IL-10* removal³². However, some meta-analysis studies have not found significant differences in *IL-10* levels between subjects with mild cognitive impairment (MCI) and healthy controls. Moreover, *IL-10* overexpressing in AD animal models weakened the phagocytosis of soluble A β by microglia and exacerbated A β deposits in cognitive impairment. They highlighted that the association of *IL-10* with AD requires further study based on genetic polymorphisms as well as the changing levels of this cytokine in AD patients³⁶.

Alzheimer disease and *IL10* gene polymorphisms

The pro- and anti-inflammatory cytokine genes have been studied as potential candidates for the individual's susceptibility to AD; however, no preferential role has been clearly identified³⁷, even with opposing results³⁸ (Table).

Interleukin -10 is encoded by a gene located on the long arm of chromosome 1 between positions 31 and 32³⁹. The regulatory regions of the *IL-10* gene have been associated with chronic inflammatory diseases, such as systemic lupus erythematosus, rheumatoid arthritis, Sjogren's syndrome, as well as the development of dementia^{9,40}. Some polymorphisms have been associated with *IL-10* gene expression (Figure).

Several single nucleotide polymorphisms (SNPs) in the regulatory region of *IL-10* were reported to be associated with modulation of *IL-10* production. This may result in an imbalance of the regulatory effect of *IL-10* on pro-inflammatory cytokines with a subsequent imbalance of the immune response^{41,42}. Lio et al.⁴¹ evaluated the role of *IL-10* polymorphisms and AD development in a group of patients from northern Italy. In 132 AD patients and 213 healthy controls, they investigated the prevalence of SNPs -1082A/G, -819C/T (rs1800871) and -592C/A (rs1800872) in the *IL-10* promoter region. The frequency of -1082A carriers, which are associated with a low production of *IL-10*, was significantly increased among AD patients. Thus, these authors concluded that the presence of the -1082A allele, associated with a low production of *IL-10*, may be considered as an additive and independent genetic risk factor for AD⁴¹. In the same year, Depboylu et al.⁴⁰ investigated the polymorphisms -1087A/G (rs1800896), -824C/T (rs1800871) and -597C/A (rs1800872) in 406 AD patients and 251 unrelated healthy controls from Germany. They found no significant differences in the allelic distribution of these polymorphisms between AD patients and controls.

Arosio et al.⁴³ investigated the prevalence of -1082A/G, -819C/T and -592C/A polymorphisms and *IL-10* production by peripheral blood mononuclear cells in 65 AD patients and 65 controls, selected from an Italian population. In the AD patients, an increase of the -1082A allele and a decrease of -1082GG genotype frequencies were observed. They found that the homozygosity for the A allele was associated with a higher risk of AD. The same authors, six years later, analyzed the genotype and allele frequencies of *IL-10* -1082A/G polymorphism in 138 patients with MCI diagnosed, respectively, as amnesic (a-MCI) and with multiple impaired cognitive domains (mcd-MCI) in Caucasians from northern Italy⁴⁴. The allele frequencies of this SNP in a-MCI patients were similar to those of AD patients, whereas those of mcd-MCI patients were comparable to controls. According to the authors, *IL-10* may partly explain the conversion of a-MCI to AD, or be a genetic marker of susceptibility^{43,44}.

In addition, studying the Italian population, Scassellati et al. analyzed 215 AD patients and 153 controls. They observed that three SNPs (-1082A/G, -819C/T and -592C/A) were in linkage disequilibrium, resulting in three haplotypes GCC, ACC and ATA. The haplotype GCC/ACC was more frequent in AD patients⁴. Some years later, another study involving an Italian population investigated allele frequency and distribution of the -1082A/G and -819C/T polymorphisms in 222 sporadic AD patients and 179 normal controls. They found that haplotype -1082A/-819T was significantly associated with an increased risk of developing AD⁴⁵.

Ma et al.⁴⁶ investigated three SNPs (-1082A/G, -819C/T and -592C/A) in 95 AD patients and 117 age-matched healthy Chinese subjects. They found a strong association between AD and two *IL-10* polymorphisms. The reduced expression of *IL-10* was associated with the -819C and -592C alleles, and the authors concluded that the functional polymorphisms of the *IL-10* gene act as a risk factor for AD.

Table. Association between IL-10 polymorphisms and Alzheimer's disease (AD) in different studies.

Authors	Location	Groups	IL-10 polymorphism(s)	Conclusion
Depboylu et al., ⁴⁰ 2003	Germany	AD: 406 Control: 251	-1087A/G -824C/T -597C/A	No significant differences have been found between AD patients and controls.
Lio et al., ⁴¹ 2003	Italy	AD: 132 Control: 213	-1082A/G -819C/T -592C/A	The presence of -1082A allele associated with a low production of IL-10, may be considered as an additive and independent genetic risk factor for AD.
Scassellati et al., ⁴ 2004	Italy	AD: 215 Control: 153	-1082G/A -819C/T -592C/A	Haplotype frequencies did not reveal differences. However, the genotype GCC/ACC was more frequent in AD.
Arosio et al., ⁴³ 2004	Italy	AD: 65 Control: 65	-1082A/G -819C/T -592C/A	In AD there was a significant increase of the -1082A allele and a decrease of -1082GG genotype frequencies.
Ma et al., ⁴⁶ 2005	China	AD: 95 Control: 117	-1082A/G -819C/T -592C/A	The reduced expression of IL-10 was associated with the -819C and -592C alleles.
Culpan et al., ³⁹ 2006	England	AD: 160 Control: 92	-3538T/A/-1354G/A -1082A/G/-819C/T -592C/A	None of the SNPs found to be associated with AD.
Ramos et al., ⁴⁸ 2006	America	AD: 265 Control: 347	-1082A/G -592C/A	No difference was observed between AD patients and controls.
Bagnoli et al., ⁴⁵ 2007	Italy	AD: 222 Control: 179	-1082A/G -819C/T	Haplotype -1082A/-819T was associated with an increase in the risk of developing AD.
Vural et al., ⁴⁹ 2009	Turkey	AD: 101 Control: 138	-1082A/G	Heterozygous (AG) or A allele carriers (AG+AA genotype) were associated with approximately two-fold increase in the risk of AD.
Combarros et al., ²⁵ 2009	England, Spain, Netherland and Germany	AD: 1. 757 Control: 6. 295	-1082A/G	Dysregulation of the <i>IL-10</i> gene contributes to chronic low-grade inflammation in some elderly people and increases the risk of AD.
Arosio et al., ⁴⁴ 2010	Italy	MCI: 138 AD and Control: Arosio et al., 2004	-1082A/G	The allele frequencies of this SNP in a-MCI subjects were similar to those of AD patients, whereas those of mcd-MCI were comparable to controls.
Ribizzi et al., ⁵⁰ 2010	Caucasian population	AD: 19 Control: 20	-1082A/G -819C/T	The -819C allele was raised in AD group and associated with low producers of IL-10.
Moraes et al., ⁴² 2013	Brazil	AD: 120 Control: 412	-1082A/G	The SNP -1082A/G exhibited an effect in predisposition to the onset of AD. Almost 40% lower chance of AD among homozygotes of the <i>IL10</i> -1082A allele.
Kang et al., ⁵³ 2015	Korea	AD: 86 No AD: 625	-1082A/G	No significant association between AD patients and No AD patients.
Vargas-Alarcón et al., ⁵⁴ 2016	Mexico	AD: 122	-1082A/G	Identified two risk haplotypes (ATA and CTA) and four protection haplotypes (ATG, CTG, ACG and CCG).
		Vascular dementia: 67	-819C/T	
Fraga et al., ⁵⁶ 2016	Brazil	Mixed dementia: 32	-1082A/G	Haplotype -1082/-819/-592, associated with lower expression of IL-10 were more frequent in patient group.
		Control: 986	-819C/T	
		Cognitive impairment: 135	-1082A/G	
		Control: 124	-819C/T	
			-592C/A	

AD: Alzheimer's disease; MCI: mild cognitive impairment.




Figure. Chromosome 1, *IL-10* gene and SNPs in promoter region.

Culpan et al.⁴⁷, in a retrospective case-control study, examined the brain tissue from 160 patients with neuropathologically confirmed AD and 92 neuropathologically normal non-demented elderly controls, from a population in England. They evaluated five SNPs -3538T/A (rs1800890), -1354G/A (rs1800893), -1082A/G, -819C/T, -592C/A, and two microsatellites (IL-10-G, IL-10-R) in the promoter region of the *IL-10* gene. None of the SNPs or microsatellites was found to be associated with AD. Levels of IL-10 protein and gene expression also did not appear to be related to AD. These results are consistent with those reported in Italian and German patients^{4,40}, but differed from those in others studies in Italian and Chinese populations^{41,43,45,46}.

In the same year, Ramos et al.⁴⁸ evaluated the influence of promoter region polymorphisms in the *IL-10* gene and the risk of late-onset AD in 265 older white patients and 347 white control subjects in the American population. No difference was observed for *IL-10*-1082A/G and -592C/A allelic and genotypic frequencies between the groups.

Vural et al.⁴⁹ investigated the SNP-1082A/G as a susceptibility factor for AD in 101 sporadic AD patients and 138 healthy controls in the Turkish population. Heterozygous (AG) or A allele carriers (AG+AA genotype) for this polymorphism were associated with approximately a two-fold increase in the risk of AD.

Ribizzi *et al.*, also analyzing Caucasian individuals, evaluated the genotypic and allelic polymorphisms of 10 cytokine genes (*IL-1A*, *IL-1B*, *IL-2*, *IL-4*, *IL-6*, *IL-10*, *IL-12*, *IFN- γ* ,

TGF- β , *TNF- α*), and of cytokine receptors (*IL-1R*, *IL-1RA*, *IL-4RA*) in 19 AD patients and 20 controls affected by non-inflammatory neuropsychiatric disease. They suggested the presence of a pro-inflammatory environment in AD patients, corroborated by the low expression of *IL-10* when the -819C allele was present⁵⁰.

Zhang et al.⁵⁰ performed a meta-analysis on the association between *IL-10* -1082A/G polymorphism and AD risk (2,158 patients and 2,088 controls in 12 case-control studies)⁵¹. The results indicated that A allele carriers (AA + AG) had a 27% increased risk of AD, when compared with the homozygote GG. In the analysis of the ethnic subgroup, significant elevated risk was associated with A allele carriers in Europeans but not in Asians, suggesting genetic diversity among ethnicities. However, because there was only one study performed in Asians, these results may not be valid for this population, according to the authors⁴⁷. Di Bona et al.⁵² also investigated, by meta-analysis, the association of the common *IL-10* polymorphisms with AD risk. Fifteen studies investigating the association between the polymorphisms -1082A/G, -819C/T and -592C/A and AD were analyzed. The data suggested an association between the -1082A allele and risk of AD. They did not find an association with AD for the -819C/T and -592C/A polymorphisms.

Moraes et al.⁴² compared the polymorphic genotype distribution across outpatients with late-onset AD and non-cognitively impaired subjects (120 AD patients and 412 healthy controls) from Brasília, midwest Brazil. They evaluated polymorphisms in *IL-1 α* , *IL-1 β* , *IL-6*, *IL-8*, *IL-10*, *IL-12 β* ,

IL-18, *TGF-β1*, *TLR-4* and *TNF-α* genes. Only *IL-10* (-1082A/G) and *IL6* (-174C, rs1800795) genes, in recessive and dominant models, respectively, exhibited an effect on the predisposition to AD. Their findings showed an almost 40% lower chance of AD among homozygotes of the *IL-10*-1082A allele⁴².

Kang et al.⁵³ investigated the involvement of alleles associated with higher production of proinflammatory and lower production of anti-inflammatory cytokines in 732 elderly Korean individuals with AD or depression. Genotyping was performed for six pro-inflammatory (*IL-1β*, *IL-6*, *IL-8*, *TNF-α*) and two anti-inflammatory (*IL-4* and *IL-10*-1082A/G) cytokines genes. *TNF-α* and *IL-8* were significantly associated with AD, and *IL-1β* with late-life depression. They found no significant association between anti-inflammatory cytokine gene polymorphisms and AD or late-life depression⁵³.

Vargas-Alarcón et al.⁵⁴ conducted the first study in a Mexican population that considered the analysis of *IL-10* SNPs in patients with AD, vascular dementia and mixed dementia (AD/vascular dementia). They analyzed genotypes, allele distributions and haplotypes of *IL-10* promoter polymorphisms -592 C/A, -819 C/T and -1082 A/G, in 986 healthy controls and 221 patients, with 122 patients with AD, 67 with vascular dementia and 32 with mixed dementia. They observed associations between the *IL-10* SNPs with mixed dementia when compared with controls, with dominant, and overdominant inheritance models⁵⁴. Moreover, these polymorphisms were associated with a lower risk of developing AD and vascular dementia when compared with controls. Patients with dementia also showed increased frequency of ATA, CTG, and CTA haplotypes when compared with controls. They identified two risk haplotypes: ATA and CTA and four protection haplotypes: ATG, CTG, ACG and CCG⁵⁴.

Mun et al.⁵⁵, in a meta-analysis, re-evaluated and updated the associations between IL gene polymorphisms [-889C > T (rs1800587) in *IL-1α*, -511C > T (rs16944) in *IL-1β*, -174C > G (rs1800795) in *IL-6* and -1082G > A in *IL-10*] and the risk of AD. Their results suggested that the -889C > T polymorphism may be a potential risk factor in AD. However, the other three polymorphisms, including the -1082G > A polymorphism of *IL-10*, may not be a risk factor for AD⁵⁵.

Our group investigated the frequency of *IL-10*-1082A > G, -819C > T and -592C > A SNPs in a sample of healthy and cognitively impaired elderly, to verify the association between

these SNPs and the cognitive and functional performance of individuals aged 75 years and above. In this study, 259 Brazilian participants were included, 135 with cognitive impairment (81 with cognitive impairment with no dementia, and 54 demented seniors) and 124 age-matched and gender-matched cognitively healthy controls. The results showed that the haplotypes associated with lower gene expression were more frequent among individuals with cognitive impairment. Moreover, carriers of the -1082G allele also had better performances in brief cognitive screening tests. Carriers of -819T and -592A alleles showed worse performance than non-carriers in the same tests. In relation to the *IL-10* haplotypes, individuals with higher or intermediate expression of IL-10 had better performances in the screening tests. The results suggest a potential role for these SNPs in the development of cognitive impairment with no dementia, and dementia, which may influence the cognitive performance of these patients⁵⁶.

The discrepancies between the studies may be explained by uncontrolled confounding factors, gene-gene interaction or by the fact that some polymorphisms present with different allelic frequencies in certain populations, since genotype distribution of *IL-10* polymorphisms has been found to be different in Caucasian and Asian populations²⁶.

None the studies discussed found differences in either IL-10 haplotype or genotype distributions among AD patients who did, or did not, carry the allele 4 (epsilon4) of the *Apolipoprotein E* gene, concluding that the *IL-10* polymorphisms are an additive and independent risk factor for AD.

CONCLUSION

The studies showed that immunity has an important role in AD onset/progress. Although *IL-10* SNP frequency has shown heterogeneity in different populations, several studies, including our investigation in a Brazilian cohort, suggest that these polymorphisms, particularly -1082A/G, are an important risk factor for AD. However, the mechanism in which IL-10 may ameliorate neuroinflammation, cognitive dysfunction or neurodegeneration is not completely clear. Therefore, other molecular studies, to clarify the AD etiology, are necessary for solution management and prevention of this complex disease.

References

1. Alzheimer's Association. 2015 Alzheimer's disease facts and figures. *Alzheimers Dement*. 2015;11(3):332-84. <https://doi.org/10.1016/j.jalz.2015.02.003>
2. Heppner FL, Ransohoff RM, Becher B. Immune attack: the role of inflammation in Alzheimer disease. *Nat Rev Neurosci*. 2015;16(6):358-72. <https://doi.org/10.1038/nrn3880>
3. Nitri R, Bottino CM, Albala C, Custodio Capuñay NS, Ketzoian C, Llibre Rodríguez JJ et al. Prevalence of dementia in Latin America: a collaborative study of population-based cohorts. *Int Psychogeriatr*. 2009;21(4):622-30. <https://doi.org/10.1017/S1041610209009430>
4. Scassellati C, Zanardini R, Squitti R, Bocchio-Chiavetto L, Bonvicini C, Binetti G et al. Promoter haplotypes of interleukin-10 gene and sporadic Alzheimer's disease. *Neurosci Lett*. 2004;356(2):119-22. <https://doi.org/10.1016/j.neulet.2003.11.033>
5. Swardfager W, Lanctôt K, Rothenburg L, Wong A, Cappell J, Herrmann N. A meta-analysis of cytokines in Alzheimer's disease. *Biol Psychiatry*. 2010;68(10):930-41. <https://doi.org/10.1016/j.biopsych.2010.06.012>
6. Rosenberg RN, Lambracht-Washington D, Yu G, Xia W. Genomics of Alzheimer disease: a review. *JAMA Neurol*. 2016;73(7):867-74. <https://doi.org/10.1001/jamaneurol.2016.0301>

7. Blach-Olszewska Z, Zaczynska E, Gustaw-Rothenberg K, Avila-Rodrigues M, Barreto GE, Leszek J et al. The innate immunity in Alzheimer disease- relevance to pathogenesis and therapy. *Curr Pharm Des.* 2015;21(25):3582-8. <https://doi.org/10.2174/1381612821666150710144829>
8. Dubois RN. The Jeremiah Metzger Lecture: inflammation, immune modulators, and chronic disease. *Trans Am Clin Climatol Assoc.* 2015;126:230-6.
9. Sardi F, Fassina L, Venturini L, Inguscio M, Guerriero F, Rolfo E et al. Alzheimer's disease, autoimmunity and inflammation: the good, the bad and the ugly. *Autoimmun Rev.* 2011;11(2):149-53. <https://doi.org/10.1016/j.autrev.2011.09.005>
10. Kiyota T, Ingraham KL, Swan RJ, Jacobsen MT, Andrews SJ, Ikezu T. AAV serotype 2/1-mediated gene delivery of anti-inflammatory interleukin-10 enhances neurogenesis and cognitive function in APP+PS1 mice. *Gene Ther.* 2012;19(7):724-33. <https://doi.org/10.1038/gt.2011.126>
11. Delaby C, Gabelle A, Blum D, Schraen-Maschke S, Moulinier A, Boulanghien J et al. Central Nervous System and Peripheral Inflammatory Processes in Alzheimer's Disease: Biomarker Profiling Approach. *Front Neurol* 2015 Aug;6:181. <https://doi.org/10.3389/fneur.2015.00181> PMID:26379616
12. Naert G, Rivest S. The role of microglial cell subsets in Alzheimer's disease. *Curr Alzheimer Res.* 2011;8(2):151-5. <https://doi.org/10.2174/156720511795256035>
13. Fuster-Matanzo A, Llorens-Martín M, Hernández F, Avila J. Role of neuroinflammation in adult neurogenesis and Alzheimer disease: therapeutic approaches. *Mediators Inflamm.* 2013;2013:260925. <https://doi.org/10.1155/2013/260925>
14. Latta CH, Brothers HM, Wilcock DM. Neuroinflammation in Alzheimer's disease: a source of heterogeneity and target for personalized therapy. *Neuroscience.* 2015;302:103-11. <https://doi.org/10.1016/j.neuroscience.2014.09.061>
15. Steardo L Jr, Bronzuoli MR, Iacomino A, Esposito G, Steardo L, Scuderi C. Does neuroinflammation turn on the flame in Alzheimer's disease? Focus on astrocytes. *Front Neurosci.* 2015;9:259. <https://doi.org/10.3389/fnins.2015.00259>
16. Singhal G, Jaehne EJ, Corrigan F, Toben C, Baune BT. Inflammasomes in neuroinflammation and changes in brain function: a focused review. *Front Neurosci.* 2014;8:315. <https://doi.org/10.3389/fnins.2014.00315>
17. Alam Q, Alam MZ, Mushtaq G, Damanhoury GA, Rasool M, Kamal MA et al. Inflammatory process in Alzheimer's and Parkinson's diseases: central role of cytokines. *Curr Pharm Des.* 2016;22(5):541-8. <https://doi.org/10.2174/1381612822666151125000300>
18. Saleem M, Herrmann N, Swardfager W, Eisen R, Lanctôt KL. Inflammatory Markers in Mild Cognitive Impairment: A Meta-Analysis. *J Alzheimers Dis.* 2015;47(3):669-79. <https://doi.org/10.3233/JAD-150042>
19. Verkhatsky A, Zorec R, Rodríguez JJ, Parpura V. Astroglia dynamics in ageing and Alzheimer's disease. *Curr Opin Pharmacol.* 2016;26:74-9. <https://doi.org/10.1016/j.coph.2015.09.011>
20. Julian A, Dugast E, Ragot S, Krolak-Salmon P, Berrut G, Dantoine T et al. There is no correlation between peripheral inflammation and cognitive status at diagnosis in Alzheimer's disease. *Aging Clin Exp Res.* 2015;27(5):589-94. <https://doi.org/10.1007/s40520-015-0332-5>
21. Sabat R. IL-10 family of cytokines. *Cytokine Growth Factor Rev.* 2010;21(5):315-24. <https://doi.org/10.1016/j.cytogfr.2010.11.001>
22. Bagyinszky E, Youn YC, An SS, Kim SY. Characterization of inflammatory biomarkers and candidates for diagnosis of Alzheimer's disease. *Biochip J.* 2014;8(3):155-62. <https://doi.org/10.1007/s13206-014-8301-1>
23. Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. *J Exp Med.* 1989;170(6):2081-95. <https://doi.org/10.1084/jem.170.6.2081>
24. Acuner-Ozbabacan ES, Engin BH, Guven-Maiorov E, Kuzu G, Muratcioglu S, Baspinar A et al. The structural network of Interleukin-10 and its implications in inflammation and cancer. *BMC Genomics.* 2014;15 Suppl 4:S2. <https://doi.org/10.1186/1471-2164-15-S4-S2>
25. Combarros O, Duijn CM, Hammond N, Belbin O, Arias-Vásquez A, Cortina-Borja M et al. Replication by the Epistasis Project of the interaction between the genes for IL-6 and IL-10 in the risk of Alzheimer's disease. *J Neuroinflammation.* 2009;6(1):22. <https://doi.org/10.1186/1742-2094-6-22>
26. Ma SL, Tang NL, Lam LC, Chiu HF. The association between promoter polymorphism of the interleukin-10 gene and Alzheimer's disease. *Neurobiol Aging.* 2005;26(7):1005-10. <https://doi.org/10.1016/j.neurobiolaging.2004.08.010>
27. Rota E, Bellone G, Rocca P, Bergamasco B, Emanuelli G, Ferrero P. Increased intrathecal TGF-beta1, but not IL-12, IFN-gamma and IL-10 levels in Alzheimer's disease patients. *Neuro Sci.* 2006;27(1):33-9. <https://doi.org/10.1007/s10072-006-0562-6>
28. Richwine AF, Sparkman NL, Dilger RN, Buchanan JB, Johnson RW. Cognitive deficits in interleukin-10-deficient mice after peripheral injection of lipopolysaccharide. *Brain Behav Immun.* 2009;23(6):794-802. <https://doi.org/10.1016/j.bbi.2009.02.020>
29. Henderson VW. Estrogen-containing hormone therapy and Alzheimer's disease risk: understanding discrepant inferences from observational and experimental research. *Neuroscience.* 2006;138(3):1031-9. <https://doi.org/10.1016/j.neuroscience.2005.06.017>
30. Ishunina TA, Fischer DF, Swaab DF. Estrogen receptor alpha and its splice variants in the hippocampus in aging and Alzheimer's disease. *Neurobiol Aging.* 2007;28(11):1670-81. <https://doi.org/10.1016/j.neurobiolaging.2006.07.024>
31. Luchetti S, Bossers K, Van de Bilt S, Agrapart V, Morales RR, Frajese GV et al. Neurosteroid biosynthetic pathways changes in prefrontal cortex in Alzheimer's disease. *Neurobiol Aging.* 2011;32(11):1964-76. <https://doi.org/10.1016/j.neurobiolaging.2009.12.014>
32. Cianciulli A, Dragone T, Calvello R, Porro C, Trotta T, Lofrumento DD et al. IL-10 plays a pivotal role in anti-inflammatory effects of resveratrol in activated microglia cells. *Int Immunopharmacol.* 2015;24(2):369-76. <https://doi.org/10.1016/j.intimp.2014.12.035>
33. Guillot-Sestier MV, Doty KR, Gate D, Rodriguez J Jr, Leung BP, Rezai-Zadeh K et al. IL10 deficiency rebalances innate immunity to mitigate Alzheimer-like pathology. *Neuron* 2015;85(3):534-48. <https://doi.org/10.1016/j.neuron.2014.12.068>
34. Chakrabarty P, Li A, Ceballos-Diaz C, Eddy JA, Funk CC, Moore B et al. IL-10 alters immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior. *Neuron.* 2015;85(3):519-33. <https://doi.org/10.1016/j.neuron.2014.11.020>
35. Bryson KJ, Lynch MA. Linking T cells to Alzheimer's disease: from neurodegeneration to neurorepair. *Curr Opin Pharmacol.* 2016;26:67-73. <https://doi.org/10.1016/j.coph.2015.10.003>
36. Zheng C, Zhou XW, Wang JZ. The dual roles of cytokines in Alzheimer's disease: update on interleukins, TNF- α , TGF- β and IFN- γ . *Transl Neurodegener.* 2016;5(1):7. <https://doi.org/10.1186/s40035-016-0054-4>
37. Fraga VG, Guimarães HC, Lara VP, Teixeira AL, Barbosa MT, Carvalho MG et al. TGF- β 1 Codon 10 T>C polymorphism influences short-term functional and cognitive decline in healthy oldest-old individuals: the Pietà study. *J Alzheimers Dis.* 2015;48(4):1077-81. <https://doi.org/10.3233/JAD-150397>
38. Cousin E, Macé S, Rocher C, Dib C, Muzard G, Hannequin D et al. No replication of genetic association between candidate polymorphisms and Alzheimer's disease. *Neurobiol Aging.* 2011;32(8):1443-51. <https://doi.org/10.1016/j.neurobiolaging.2009.09.004>
39. Culpan D, Prince JA, Matthews S, Palmer L, Hughes A, Love S et al. Neither sequence variation in the IL-10 gene promoter nor presence of IL-10 protein in the cerebral cortex is associated with Alzheimer's disease. *Neurosci Lett.* 2006;408(2):141-5. <https://doi.org/10.1016/j.neulet.2006.08.068>

40. Depboylu C, Du Y, Müller U, Kurz A, Zimmer R, Riemenschneider M et al. Lack of association of interleukin-10 promoter region polymorphisms with Alzheimer's disease. *Neurosci Lett*. 2003;342(1-2):132-4. [https://doi.org/10.1016/S0304-3940\(03\)00231-3](https://doi.org/10.1016/S0304-3940(03)00231-3)
41. Lio D, Licastro F, Scola L, Chiappelli M, Grimaldi LM, Crivello A et al. Interleukin-10 promoter polymorphism in sporadic Alzheimer's disease. *Genes Immun*. 2003;4(3):234-8. <https://doi.org/10.1038/sj.gene.6363964>
42. Moraes CF, Benedet AL, Souza VC, Lins TC, Camargos EF, Naves JO et al. Cytokine gene polymorphisms and Alzheimer's disease in Brazil. *Neuroimmunomodulation*. 2013;20(5):239-46. <https://doi.org/10.1159/000350368>
43. Arosio B, Trabattoni D, Galimberti L, Bucciarelli P, Fasano F, Calabresi C et al. Interleukin-10 and interleukin-6 gene polymorphisms as risk factors for Alzheimer's disease. *Neurobiol Aging*. 2004;25(8):1009-15. <https://doi.org/10.1016/j.neurobiolaging.2003.10.009>
44. Arosio B, Mastronardi L, Vergani C, Annoni G. Interleukin-10 promoter polymorphism in mild cognitive impairment and in its clinical evolution. *Int J Alzheimers Dis*. 2010;20:pii 854527. <https://doi.org/10.4061/2010/854527>
45. Bagnoli S, Cellini E, Tedde A, Nacmias B, Piacentini S, Bessi V et al. Association of IL10 promoter polymorphism in Italian Alzheimer's disease. *Neurosci Lett*. 2007;418(3):262-5. <https://doi.org/10.1016/j.neulet.2007.03.030>
46. Ma SL, Tang NL, Lam LC, Chiu HF. The association between promoter polymorphism of the interleukin-10 gene and Alzheimer's disease. *Neurobiol Aging*. 2005;26(7):1005-10. <https://doi.org/10.1016/j.neurobiolaging.2004.08.010>
47. Culpán D, Prince JA, Matthews S, Palmer L, Hughes A, Love S et al. Neither sequence variation in the IL-10 gene promoter nor presence of IL-10 protein in the cerebral cortex is associated with Alzheimer's disease. *Neurosci Lett*. 2006;408(2):141-5. <https://doi.org/10.1016/j.neulet.2006.08.068>
48. Ramos EM, Lin MT, Larson EB, Maezawa I, Tseng LH, Edwards KL et al. Tumor necrosis factor alpha and interleukin 10 promoter region polymorphisms and risk of late-onset Alzheimer disease. *Arch Neurol*. 2006;63(8):1165-9. <https://doi.org/10.1001/archneur.63.8.1165>
49. Vural P, Değirmencioğlu S, Parildar-Karpuzoğlu H, Dođru-Abbasođlu S, Hanagasi HA, Karadađ B et al. The combinations of TNFalpha-308 and IL-6 -174 or IL-10 -1082 genes polymorphisms suggest an association with susceptibility to sporadic late-onset Alzheimer's disease. *Acta Neurol Scand*. 2009;120(6):396-401. <https://doi.org/10.1111/j.1600-0404.2009.01230.x>
50. Ribizzi G, Fiordoro S, Barocci S, Ferrari E, Megna M. Cytokine polymorphisms and Alzheimer disease: possible associations. *Neurol Sci*. 2010;31(3):321-5. <https://doi.org/10.1007/s10072-010-0221-9>
51. Zhang Y, Zhang J, Tian C, Xiao Y, Li X, He C et al. The -1082G/A polymorphism in IL-10 gene is associated with risk of Alzheimer's disease: a meta-analysis. *J Neurol Sci* 2011;303(1-2):133-8. <https://doi.org/10.1016/j.jns.2010.12.005>
52. Di Bona D, Rizzo C, Bonaventura G, Candore G, Caruso C. Association between interleukin-10 polymorphisms and Alzheimer's disease: a systematic review and meta-analysis. *J Alzheimers Dis*. 2012;29(4):751-9. <https://doi.org/10.3233/JAD-2012-111838>
53. Kang HJ, Kim JM, Kim SW, Shin IS, Park SW, Kim YH et al. Associations of cytokine genes with Alzheimer's disease and depression in an elderly Korean population. *J Neurol Neurosurg Psychiatry*. 2015;86(9):1002-7. <https://doi.org/10.1136/jnnp-2014-308469>
54. Vargas-Alarcón G, Juárez-Cedillo E, Martínez-Rodríguez N, Fragoso JM, García-Hernández N, Juárez-Cedillo T. Association of interleukin-10 polymorphisms with risk factors of Alzheimer's disease and other dementias (SADEM study). *Immunol Lett*. 2016;177:47-52. <https://doi.org/10.1016/j.imlet.2016.07.011>
55. Mun MJ, Kim JH, Choi JY, Jang WC. Genetic polymorphisms of interleukin genes and the risk of Alzheimer's disease: an update meta-analysis. *Meta Gene*. 2016;8:1-10. <https://doi.org/10.1016/j.mgene.2016.01.001>
56. Fraga VG, Guimarães HC, Teixeira AL, Barbosa MT, Carvalho MG, Caramelli P et al. Polymorphisms in cytokine genes influence cognitive and functional performance in a population aged 75 years and above. *Int J Geriatr Psychiatry*. 2016;2016. <https://doi.org/10.1002/gps.4627>